Precision Oncology .

Precision Oncology has rebranded as Precision for Medicine, Oncology and Rare Disease, reflecting its comprehensive services in clinical development, translational sciences, and clinical development planning. This transformation underscores its commitment to accelerating the drug development pathway by integrating advanced scientific methods and targeting specific patient populations. With the acquisition of Agility Clinical, Precision for Medicine, Oncology and Rare Disease has expanded its focus to include rare diseases, including rare cancers, enhancing its expertise in both oncology and rare disease-specific studies.

The company's new name signifies a broader scope and a renewed commitment to providing specialized expertise and study teams. This strategic move positions Precision for Medicine, Oncology and Rare Disease as a leader in the field, offering a unique blend of services that are not typically found in traditional Contract Research Organizations (CROs). By focusing on rare diseases and orphan therapies, the company aims to address unmet medical needs and contribute to the development of innovative treatments.

With its headquarters in Flemington, New Jersey, Precision for Medicine, Oncology and Rare Disease continues to serve its clients with a dedicated team of 27 employees, offering a private, client-focused approach to clinical development. The company's dedication to advancing medical science and improving patient outcomes makes it a valuable partner for organizations seeking to navigate the complexities of drug development in oncology and rare diseases.